Robert Weisman

Weisman covers the healthcare and life sciences industries for the Business section. He was a business reporter and editor for the Hartford Courant and the Seattle Times before joining the Globe in 2000.

Latest stories

Biotechs take lead in a new push against neurological disorders

By , Globe Staff

Local biotechs are developing drugs for neurological disorders like Alzheimer’s and Huntington’s diseases.

Vertex CEO’s pay falls 38% to $17.4m in second straight decline

By , Globe Staff

Jeffrey M. Leiden’s compensation fell 38 percent in 2016, mostly on a cut in his stock-option awards.

Alere agrees to be bought by Abbott for reduced price

By , Globe Staff

Four months after Abbott Laboratories sued to terminate its merger deal with Waltham’s Alere Inc., the companies Friday said they plan to complete the transaction .

Gene-editing patents face challenge from expanded group

By , Globe Staff

Two biotech startups developing drugs with a promising gene-editing tool have joined a consortium of companies and universities challenging a US patent court’s ruling in favor of the Broad Institute of MIT and Harvard.